Camurus AB (CHIX:CAMXS) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CAMXS Camurus AB CHIX:CAMXS
84 GF Score
Price kr615.75
GF Value kr677.85
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Camurus AB Defensive Interval Ratio?

CHIX:CAMXS
84GF Score
Camurus AB CHIX:CAMXS
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (CHIX:CAMXS) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of kr615.75 is trading 9.2% below its estimated GF Value™ of kr677.85. GuruFocus considers Camurus AB to be Fairly Valued.

Key valuation signals for CHIX:CAMXS:

  • Defensive Interval Ratio:
  • GF Value™: kr677.85 vs. price of kr615.75 (9.2% below fair value)
  • GF Score™: 84/100 with 2 warning signs

No single metric tells the full story. See the CHIX:CAMXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
84GF Score

Get the complete analysis for CHIX:CAMXS

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr615.75
Price
kr677.85
GF Value